Treatment of hypertriglyceridemia with fibric acid derivatives: Impact on lipid subfractions and translation into a reduction in cardiovascular events

Reviews in Cardiovascular Medicine

Volumn 12, Issue 4, 2011, Pages 173-185

  McCullough, Peter A ^a   Ahmed, Amina B ^a   Zughaib, Marc T ^a   Glanz, Eric D ^a   Di Loreto, Michael J ^a  

^a St John Providence Health System   (United States)

Author keywords

Cardiovascular events; Dyslipidemia; Fibrates; Hypertriglyceridemia

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANXIETY; CARDIOVASCULAR SYMPTOM; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; EPIDERMOLYSIS; FRACTIONATION; HEADACHE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MYOSITIS; NAUSEA; PARTICLE SIZE; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84855557895     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0619     Document Type: Review

References (68)

1. Jonkers IJ, Smelt AH, van der Laarse A. Hypertriglyceridemia associated risks and effect of drug treatment. Am J Cardiovasc Drugs. 2001;1:455-466.
2. Parzianello L, Oliveira G, Coelho JC. Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil. Braz J Med Biol Res. 2008;41:462-467.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891-897.
5. Vogel JA, Franklin BA, Zalesin KC, et al. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol. 2007;99:222-226. (Pubitemid 46072757)
6. Manfredini F, D'Addato S, Laghi L, et al. Influence of lifestyle measures on hypertriglyceridaemia. Curr Drug Targets. 2009;10:344-355.
7. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007;115:2540-2548. (Pubitemid 46763228)
8. Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV. Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs. 2008;8:243-255.
9. Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009;2009:501739.
10. Jonkers IJ, de Man FH, van der Laarse A, et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens. 2001;19:749-755. (Pubitemid 32289555)
11. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093. (Pubitemid 28512236)
12. Galimberti P, Defranceschi A. Intesi di alcuni derivati α-isobutirici. Gazz Chim Ital. 1947;77:431.
13. Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962;194:948-949.
14. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984;2:600-604.
15. Lalloyer F, Staels B. Fibrates, glitazones, and perosixome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30:894-899.
16. Vouillamoz D, Schaller MD, Bianchi L, et al. Beclobrate and fatal acute hepatitis. Lancet. 1991;338:581.
17. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11:89-94.
18. Ntaios G, Savopoulos C, Chatzopoulos S, et al. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis. 2011;214:11-19.
19. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J. 2010;31:1248-1256.
20. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536-541.
21. Forsblom C, Hiukka A, Leinonen ES, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33:215-220.
22. Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep. 2009;11:338-342.
23. Leiss O, Meyer-Krahmer K, von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J Lipid Res. 1986;27:713-723. (Pubitemid 16001332)
24. Lacut K, Le Gal G, Abalain JH, et al. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res. 2008;122:314-319. (Pubitemid 351888887)
25. Roy A, Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 2009;31:339-351.
26. Gemfibrozil (gemfibrozil) tablet [Watson Laboratories, Inc.]. DailyMed Web site. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2791. Accessed October 28, 2011.
27. Kang SI, Kang SY, Kanaly RA, et al. Rapid oxidation of ring methyl groups is the primary mechanism of biotransformation of gemfibrozil by the fungus Cunninghamella elegans. Arch Microbiol. 2009;191:509-517.
28. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators. Hypertension. 2005;46:1086-1092. (Pubitemid 41533006)
29. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563. (Pubitemid 43739414)
30. O'Neal DN, O'Brien RC, Timmins KL, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med. 1998;15:870-877. (Pubitemid 28451958)
31. Tenkanen L, Mänttäri M, Kovanen PT, et al. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-748.
32. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418. (Pubitemid 29362514)
33. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656. (Pubitemid 28545204)
34. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
35. Antara (fenofibrate) capsule [Lupin Pharma]. DailyMed Web site. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24790a18-0291-4b88-a724- acac43b616ce. Accessed October 28, 2011.
36. Vakkilainen J, Steiner G, Ansquer JC, et al. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care. 2002;25:627-628.
37. Davidson MH, Bays HE, Stein E, et al TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006;29:268-273. (Pubitemid 43865706)
38. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
39. Ginsberg HN, Elam MB, Lovato LC, et al ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
40. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28:625-634.
41. Zhu T, Awni WM, Hosmane B, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009;49:63-71.
42. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009;204:208-215.
43. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157:195-203.
44. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515-522.
45. Jones PH, Goldberg AC, Knapp HR, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010;160:759-766.
46. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs. 2010;10:175-186.
47. Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421-428.
48. Goldberg AC, Bittner V, Pepine CJ, et al. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol. 2011;107:898-905.
49. Pepine CJ, Jacobson TA, Carlson DM, et al. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol. 2010;33:609-619.
50. Sleep DJ, Mandair IS, Setze CM, Kelly MT. Effects of fenofibric acid in combination with statin therapy on low-density lipoprotein particle size in patients with mixed dyslipidemia. Atheroscler Suppl. 2010;11:79-80.
51. Voros S, Joshi PH, Vazquez G, et al. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study. J Cardiovasc Comput Tomogr. 2010;4:164-172.
52. Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood (FIRST). Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00616772. Accessed October 28, 2011.
53. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of populationbased prospective studies. J Cardiovasc Risk. 1996;3:213-219. (Pubitemid 26266496)
54. Faergeman O, Holme I, Fayyad R, et al Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459-463.
55. Cardenas GA, Lavie CJ, Cardenas V, et al. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9:239-258.
56. Geurian K, Pinson JB, Weart CW. The triglyceride connection in atherosclerosis. Ann Pharmacother. 1992;26:1109-1117.
57. Vanhecke TE, Franklin BA, Maciejko J, et al. Lipoproteins, inflammatory biomarkers, and cardiovascular imaging in the assessment of atherosclerotic disease activity. Rev Cardiovasc Med. 2009;10:51-58.
58. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897-930.
59. McCullough PA, Chinnaiyan KM, Agrawal V, et al. Amplification of atherosclerotic calcification and Mönckeberg's sclerosis: a spectrum of the same disease process. Adv Chronic Kidney Dis. 2008;15:396-412.
60. Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA. 1994;272:305-308.
61. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002;163:287-296. (Pubitemid 34615819)
62. Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev. 2005;13:240-246. (Pubitemid 41197252)
63. Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates-a pooled meta-analysis. Am J Ther. 2010;17:e182-e188.
64. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154:943-953. (Pubitemid 350001283)
65. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus-a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol. 2010;141:157-166.
66. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122:962.e1-e8.
67. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-1884.
68. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias - time for a reassessment. N Engl J Med. 2011;365:481-484.